Hot Topics
$5.35 million award in insurance company bad faith case
– Read the case summary
"Job-bias cases surge in Colorado, feds say"
– The Denver Post
"FedEx Sued For Not Letting Workers Clock In On Time"
"U.S. Supreme Court upholds right to recover compensation from drug companies for injuries"
– "Wyeth v. Levine Opinion"
– "Court allows drug label lawsuit"
– Wyeth Press Release
"Gadolinium law suits picks up pace"
– Missouri Lawyers Weekly
Wal-Mart Class Action Wage Lawsuits
"Attorney Michael Burg Leads the Hunt for Culprits in Economic Meltdown"
Janet Abaray Spearheads Class Action Suit Against Bengals
Explosion Accidents:
"Pooch alive after
Breck blast"
– Denver Post
"Baxter to Proceed with Recall of Remaining Heparin Sodium Vial Products"
– FDA
Yamaha Rhino ATV Rollover Accidents
and Injuries
"UBS Hit by
Another Lawsuit"
– Ben Levinsohn, BusinessWeek
"Hedge Funds
Frozen Shut"
– Matthew Goldstein, BusinessWeek
"MRI Contrast Can Cause Disease – Gadolinium Blamed
For Problems"
– Dayle Cedars
7News, Denver, CO
Results
$5,350,000
Jury awards a Burg Simpson client $5.35 million for Bad Faith Breach of Insurance Contract.
$1,300,000
Jury award to Englewood company to total more than $1 million for breach of fiduciary duties in Shareholder Class Action Case.
$690,000,000
Global settlement with Eli Lilly and Company regarding its product Zyprexa negotiated by a plaintiffs' attorney group including members of Burg Simpson.
$5,800,000
Hines, et al, vs. Cody Gas Company, et al: verdict for injuries, damages, losses from gas explosion.
CLICK HERE FOR MORE INFORMATION
Our Offices
40 Inverness Drive East
Denver, CO 80112
Phone: 303.792.5595
Fax: 303.708.0527
WYOMING OFFICE
Phone: 307.527.7891
Fax: 307.527.7897
OHIO OFFICE
Phone: 513.852.5600
Fax: 513.852.5611
ARIZONA OFFICE
Phone: 602.508.6040
Home > Defective Drugs > Celebrex
Celebrex Attorneys
in Denver and Nationwide
Pfizer's Celebrex (generic name: celecoxib) is the only Cox-2 inhibitor NSAID to remain on the market. Originally approved in December 1998 for the pain of osteoarthritis and rheumatoid arthritis, later indications included menstrual pain, ankylosing spondylitis, and reduction of adenomatous colorectal polyps.
In December 2004, a National Cancer Institute clinical trial investigating the use of Celebrex to prevent colon polyps was halted due to an increased risk of cardiovascular (CV) events in patients taking Celebrex versus those taking a placebo. Patients in the clinical trial taking 400 mg of Celebrex twice daily had a 3.4 times greater risk of CV events compared to those taking placebo. For patients taking 200 mg of Celebrex twice daily, the risk was 2.5 times greater. The average duration of treatment in the trial was 33 months. A similar ongoing study comparing Celebrex 400 mg once daily versus placebo, in patients followed for a similar period of time, has not shown increased risk.
On July 29, 2005, Pfizer added a black box warning to the Celebrex label, the strongest warning that the FDA can mandate. The new black box warnings include: increased risk of cardiovascular (CV) thrombotic events, including myocardial infarction and stroke; contraindication for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery; and increased risk of gastrointestinal events such as bleeding, ulceration, and perforation of the stomach or intestines.
Burg Simpson has unique experience dealing with Bextra cases. A Bextra/Celebrex MDL has now been formed in the United States District Court for the Northern District of California and Peter Burg has been appointed to the Plaintiffs' Steering Committee by Judge Charles Breyer.
If you believe you have a claim because you used Celebrex, please call or email us today for a free consultation. At Burg Simpson Eldredge Hersh & Jardine, P.C., our Colorado attorneys represent people who have suffered injuries because of Celebrex.
Return to the Defective Drugs Section
